The DZANK1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the DZANK1 gene in the HeLa cell line. This product provides a ready-to-use loss-of-function model achieved through CRISPR/Cas9-mediated gene disruption, offering a heterogeneous pool of edited cells without monoclonal isolation. Suitable for functional genomics, this tool enables investigation of DZANK1??s roles in a widely used cancer cell background.
HeLa cells originate from HPV18-positive cervical adenocarcinoma and are among the most extensively characterized immortalized cell lines in research. Their robust proliferation, ease of maintenance, and well-documented molecular landscape??including dysregulated p53 and Rb pathways due to E6/E7 oncoproteins??make them an ideal host for knockout studies. This background allows researchers to assess the impact of DZANK1 loss on cancer-associated processes in an epithelial context.
DZANK1 contains ankyrin repeat and zinc ribbon domains, indicating functions in protein-protein interactions and potential DNA binding. Although primarily studied in retinal tissues, where it may be regulated by transcription factors CRX and NRL, its function in non-retinal cells is unclear. In HeLa cells, DZANK1 likely engages in distinct interaction networks, and its disruption permits the dissection of these pathways using assays such as co-immunoprecipitation and RNA-seq. The lack of characterized downstream targets and interacting factors makes this knockout model particularly valuable for exploratory functional genomics.
The significance of this knockout in HeLa extends beyond retinal biology, enabling exploration of DZANK1 in cancer cell proliferation, apoptosis, and migration. DZANK1 mutations are associated with retinal dystrophies such as retinitis pigmentosa and cone-rod dystrophy, but its expression elsewhere suggests additional roles. Given the HPV-positive status of HeLa, this model also offers a platform to investigate potential interactions between viral oncoproteins and DZANK1-related pathways. The polyclonal format captures editing diversity, providing a realistic representation of CRISPR-induced phenotypic outcomes and facilitating off-target effect evaluation.
Applications include protein and mRNA expression analysis via Western blotting and RT-qPCR, cellular localization by immunofluorescence, and interaction partner identification through co-immunoprecipitation. High-throughput RNA-seq can delineate transcriptomic changes, while functional assays??proliferation, apoptosis, migration??reveal cancer-relevant phenotypes. This DZANK1 knockout model is a versatile resource for functional genomics and CRISPR research. For further information, please contact Ascent Research.
